MRAS
Ras-related protein M-Ras
Also known as: M-RAs, R-RAS3, RASM_HUMAN, RRAS3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O14807
- Gene
- MRAS
- Ensembl
- ENSG00000158186
- Chromosome
- 3
- Canonical length
- 208 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins
- Subcellular location
- Vesicles,Cytosol
OverviewNCBI Gene
This gene encodes a member of the Ras family of small GTPases. These membrane-associated proteins function as signal transducers in multiple processes including cell growth and differentiation, and dysregulation of Ras signaling has been associated with many types of cancer. The encoded protein may play a role in the tumor necrosis factor-alpha and MAP kinase signaling pathways. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Nov 2011]
Canonical amino-acid sequenceUniProt
208 residues, UniProt reviewed canonical sequence.
>O14807|MRAS
1 MATSAVPSDN LPTYKLVVVG DGGVGKSALT IQFFQKIFVP DYDPTIEDSY LKHTEIDNQW
61 AILDVLDTAG QEEFSAMREQ YMRTGDGFLI VYSVTDKASF EHVDRFHQLI LRVKDRESFP
121 MILVANKVDL MHLRKITREQ GKEMATKHNI PYIETSAKDP PLNVDKAFHD LVRVIRQQIP
181 EKSQKKKKKT KWRGDRATGT HKLQCVILLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MRAS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 113 nTPM
Expression across tissuesHPA
Tissue
- heart muscle: 113 nTPM
- basal ganglia: 112 nTPM
- cerebral cortex: 107 nTPM
- midbrain: 107 nTPM
- adipose tissue: 86 nTPM
- hypothalamus: 79 nTPM
Single-cell type
- adipocytes: 149 nCPM
- astrocytes: 132 nCPM
- cardiomyocytes: 127 nCPM
- late spermatids: 103 nCPM
- adrenal cortex cells: 88 nCPM
- bergmann glia: 87 nCPM
Immune cell
- non-classical monocyte: 25 nTPM
- intermediate monocyte: 4.1 nTPM
- myeloid DC: 2.7 nTPM
- classical monocyte: 2.1 nTPM
- NK-cell: 0.8 nTPM
- total PBMC: 0.8 nTPM
Brain region
- thalamus: 371 nTPM
- midbrain: 225 nTPM
- hypothalamus: 219 nTPM
- basal ganglia: 211 nTPM
- medulla oblongata: 204 nTPM
- cerebellum: 187 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MRAS.
Disease | AllUniProt
Conditions MRAS is implicated in, by any mechanism.
- Noonan syndrome 11 (NS11) MIM:618499
Disease | GeneticClinVar
5 pathogenic / likely-pathogenic of 264 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- RASopathy
- Noonan syndrome 11
- Male infertility with azoospermia or oligozoospermia due to single gene mutation
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.37
- gnomAD pLI
- 0.92
- gnomAD missense Z
- 2.33
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- actin cytoskeleton organization
- cellular response to leukemia inhibitory factor
- Ras protein signal transduction
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MRAS in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MRAS as an antibody target. Whether an autoantibody or antibody against MRAS could matter depends on whether native MRAS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MRAS is annotated at the cell surface, where native MRAS is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label MRAS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...